Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Pipeline Review, H2 2018
According to the recently published report 'Integrin Alpha V - Pipeline Review, H2 2018'; Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) pipeline Target constitutes close to 31 molecules. Out of which approximately 25 molecules are developed by companies and remaining by the universities/institutes.
Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Integrin alpha-V is a protein encoded by the ITGAV gene. Alpha-V integrins are receptors for vitronectin, cytotactin, fibronectin, fibrinogen, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin and vWF. The encoded preproprotein is proteolytically processed to generate light and heavy chains that comprise the alpha V subunit. This subunit associates with beta 1, beta 3, beta 5, beta 6 and beta 8 subunits. The heterodimer consisting of alpha V and beta 3 subunits is also known as the vitronectin receptor. This integrin regulate angiogenesis and cancer progression.
The report 'Integrin Alpha V - Pipeline Review, H2 2018' outlays comprehensive information on the Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II and Preclinical stages are 1, 6 and 18 respectively. Similarly, the universities portfolio in Preclinical stages comprises 6 molecules, respectively.
Report covers products from therapy areas Oncology, Ophthalmology, Metabolic Disorders, Musculoskeletal Disorders, Dermatology, Gastrointestinal, Respiratory, Infectious Disease, Cardiovascular and Immunology which include indications Fibrosis, Idiopathic Pulmonary Fibrosis, Persistent Corneal Epithelial Defects, Wet (Neovascular / Exudative) Macular Degeneration, Breast Cancer, Diabetic Nephropathy, Glioblastoma Multiforme (GBM), Liver Fibrosis, Metastatic Melanoma, Pancreatic Cancer, Wounds, Age Related Macular Degeneration, Coronary Artery Disease (CAD) (Ischemic Heart Disease), Diabetic Foot Ulcers, Diabetic Macular Edema, Genital Warts (Condylomata Acuminata), Malabsorption Syndrome, Metastatic Colorectal Cancer, Multiple Myeloma (Kahler Disease), Rheumatoid Arthritis, Sepsis and Venous Leg Ulcers (Crural Ulcer).
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook